Total intravenous anesthesia without neuromuscular blockers for ureteral lithotripsy in an ALS patient with orthopnea: a case report Authors: Yongxin Sun, Qianwei Zhong, Xiaoli Chu, Di Wan, Yunsheng Peng Published: 2025 ABSTRACT AbstractPatients with amyotrophic lateral sclerosis (ALS) rarely need urological surgery. This case report describes the successful use of total intravenous anesthesia (TIVA) with propofol and remifentanil combined with laryngeal mask airway (LMA) ventilation in a 55-year-old ALS patient with severe orthopnea who underwent ureteral lithotripsy. Given the progressive respiratory muscle weakness and inability to tolerate supine positioning, a tailored anesthetic approach is imperative. By avoiding neuromuscular blockers and minimizing opioid doses, we aimed to reduce postoperative respiratory depression. The procedure was completed uneventfully, with stable hemodynamics and rapid postoperative recovery. This case underscores the importance of individualized anesthetic strategies in neuromuscular disorders to optimize safety and outcomes.Keywords: Amyotrophic lateral sclerosis, ALS, Total intravenous anesthesia, TIVA, Ureteral lithotripsy, Neuromuscular blocking agents, Respiratory compromise Introduction Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder affecting both upper and lower motor neurons, with an estimated incidence of 1–5 per 100,000 individuals, characterized by muscle weakness, atrophy and bulbar palsy [1]. The age of onset is mostly between 30 and 60 years, with more males than females, resulting in muscle weakness, atrophy and eventual paralysis [2]. The anesthesia method used for ALS patients has been controversial [3]. Considering that the patient in this case did not lie flat and that intraspinal puncture was difficult and that there was a risk of spinal cord injury caused by intraspinal anesthesia, we believe that this patient was not an indication for intraspinal anesthesia. The use of muscle relaxants in general anesthesia may increase the risk of respiratory system damage and the potential deterioration risk of muscle weakness, so the anesthetic management of ALS patients is challenging. This report discusses the anesthetic considerations and management strategies of a patient with moderate-to-severe ALS who underwent ureteral lithotripsy. Case presentation A 55-year-old male (56 kg, 166 cm) with ALS, according to the El Escorial criteria, was diagnosed with ALS for 20 months [4], and the Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) score was 10 points [5]. At present, 50 mg of Riluzole tablet is taken orally every day. The patient had a history of cerebral infarction for 2 years and a history of splenectomy surgery. A neurological examination revealed that the patient had limb weakness, could not hold objects on both upper limbs, could not walk independently, could not lie flat, could not speak clearly, was slightly laborious, conscious, had dysarthria, could not extend the tongue, had tongue muscle atrophy with fibrillation, and could turn the neck and shrug the shoulders. Weakness, masticatory muscle, deltoid muscle, sternocleidomastoid muscle, limb muscle atrophy, proximal muscle strength of both upper limbs grade 3 + and distal muscle strength grade 4, and proximal muscle strength of both lower limbs grade 3 + and distal muscle strength grade 4 (manual muscle testing) were recorded. Preoperative airway assessment indicated Mallampati class II. Pulmonary function testing was unfeasible due to facial muscle spasms; the baseline SpO₂ was 95% on room air. After entering the operating room, the patient was given oxygen inhalation in a semirecumbent position, and the monitoring included 5-lead ECG monitoring, noninvasive blood pressure (NIBP) monitoring, pulse oximetry saturation (SPO2), the bispectral index (BIS), and radial arterial cannulation under local anesthesia. The basic vital signs of the patient were blood pressure (BP) 171/102 mm/Hg, heart rate 82 bpm, pulse oximetry SpO2 97%, and respiratory rate 20/min. We developed an individualized rapid sequence induction (RSI) strategy after careful deliberation, given the threefold challenges of aspiration risk, positional limitations, and fragile respiratory function in this patient. After preoxygenation for 15 min, 80 mg of propofol, 20 µg of remifentanil and 0.5 mg of atropine were injected intravenously in batches, and then the patient’s position was slowly changed to the supine position. After 3 min, To establish the airway, a size 4 laryngeal mask airway (LMA) was inserted, and air leakage was assessed, the laryngeal mask catheter was fixed, and the ventilation parameters were set to a tidal volume of 450 mL and a respiratory rate of 12/min. Anesthesia was maintained with propofol (2–3 mg/kg/h) and remifentanil (0.05–0.1 µg/kg/min), targeting a BIS of 40–60. Spontaneous respiration resumed intraoperatively, so we switched to synchronized intermittent mandatory ventilation (SIMV) (tidal volume 300–420 mL, respiratory rate 8–12/min). Hemodynamics remained stable (BP 125/71–171/102 mmHg, HR 62–90 bpm), with PetCO₂ 35–47 mmHg. At the end of the operation, the use of narcotic drugs was stopped, and the BIS value returned to 90. The patient’s position was then changed to the semirecumbent position. Thirteen minutes after the operation, the patient could open his eyes autonomously and maintain sufficient tidal volume and respiratory rate. The laryngeal mask airway catheter was then removed and transferred to the postanesthesia monitoring and treatment room (PACU). High-flow oxygen therapy was adopted in the PACU, where the patient had been closely observing whether there were signs of respiratory system damage. He was able to maintain sufficient oxygenation while breathing room air and returned to the ward for continuous monitoring and treatment after reaching the recovery standard. Total anesthesia duration was 50 min. Intraoperatively, 500 mL of lactated Ringer’s solution was administered, with a blood loss of 1 ml. We conducted 4 postoperative visits at 6 h, 12 h, 24 h and 48 h after the operation. The patient recovered well, and his pulse oxygen saturation fluctuated between 92% and 96%. No vomiting, nausea or aspiration occurred during the perioperative period. No hypoxemia, hypercapnia or respiratory failure occurred after the operation. The patient reported no obvious pain or discomfort and was satisfied with the anesthetic management. Discussion Amyotrophic lateral sclerosis (ALS), which affects upper and lower motor neurons, is a neurodegenerative disease of the motor ganglia of the anterior horn of the spinal cord and the pyramidal tract of the spinal cord [6]. The main manifestations of ALS are progressive amyotrophy and bulbar palsy [7]. This case highlights the importance of tailoring anesthesia methods for ALS patients. The choice of anesthesia type for ALS patients has been controversial. The patient’s condition developed seriously, and there was respiratory muscle weakness. When lying flat, he could not complete the breathing movement and felt extreme fear. Therefore, patients cannot undergo surgery under spinal anesthesia, taking into account operation injury and drug toxicity [8]. Demyelination in ALS increases the vulnerability of the spinal cord to the potential neurotoxic effects of local anesthetics [9]. While recent evidence (Gaik & Wiesmann [10]) indicates that regional/neuraxial anesthesia can be safe for select ALS patients, intraspinal anesthesia was not feasible in this case—primarily due to the patient’s inability to tolerate the positions required for neuraxial puncture (e.g., lateral or seated). Historical concerns about neuraxial anesthesia exacerbating neuromuscular weakness were a secondary consideration, but positional intolerance remained the primary barrier [10]. Opioids induce respiratory compromise primarily through two interconnected mechanisms: central depression and peripheral effects. For the central pathway, opioids bind to µ-opioid receptors in the brainstem respiratory center (specifically the pons and medulla), which reduces the center’s sensitivity to carbon dioxide (CO₂) and blunts the body’s inherent “drive to breathe”, The peripheral mechanism, in contrast, manifests as chest wall rigidity (particularly at higher doses). Given these dual mechanisms, ALS patients—who already present with preexisting respiratory muscle weakness (from motor neuron degeneration) and compromised bulbar protective reflexes—are far more susceptible to opioid-induced respiratory compromise than otherwise healthy individuals, tipping them toward hypoxemia (low blood oxygen) or hypercapnia (elevated blood CO₂) [11]. Opioids and inhalation anesthetics may also lead to postoperative respiratory depression [12]. Therefore, this case poses a great challenge to anesthesiologists. We used an esophageal drainage laryngeal mask airway (ED-LMA), which was inserted via blind insertion without the need for laryngoscopy. This approach avoids direct stimulation of the bulbar dysfunction-mediated protective reflexes. Additionally, the LMA’s cuff forms a seal around the laryngeal inlet (rather than entering the trachea), which reduces the risk of tracheal mucosal injury while still providing a barrier against gross aspiration—a balance critical for this patient with both aspiration vulnerability and fragile airway reflexes. Bulbar and respiratory muscle weakness mean ALS patients are at high risk of post-extubation stridor or respiratory failure. The LMA allows for earlier removal than endotracheal intubation (our patient’s LMA was removed 13 min postoperatively, once spontaneous respiration resumed) because it does not require full recovery of laryngeal adductor strength to prevent aspiration. This early removal reduced the duration of airway device-related stimulation, aligning with the patient’s need for minimal respiratory compromise. Considering the above reasons, we adopted the method of fractional titration administration of low-dose opioids combined with propofol for anesthesia induction to prevent excessive accumulation of drugs in the body and excessive hemodynamic fluctuations. To reduce the strong stimulation of endotracheal intubation, we used an LMA for ventilation, further reducing the use of opioids while avoiding violent fluctuations in hemodynamics. Propofol and remifentanil were used in combination in the maintenance phase of anesthesia to reduce the impairment of patients’ respiratory function. Although muscle relaxants were not used in this anesthesia protocol, the surgical conditions (i.e., adequate muscle relaxation) were satisfactory to the urologists, and the operation was completed successfully. The use of neuromuscular function monitoring in ALS patients is also controversial [12, 13]. We performed TIVA without muscle relaxants. Therefore, neuromuscular monitoring instruments were not used intraoperatively. We found that during the whole anesthesia induction and maintenance period, patients need only very small doses of propofol and remifentanil to maintain the appropriate depth of anesthesia. It is not clear whether this phenomenon differs among individuals or is related to the degeneration of the nervous system caused by ALS. This phenomenon needs further in-depth study. Conclusion Total Intravenous Anesthesia (TIVA) without neuromuscular blocking agents (NMBAs) is a viable option for patients with ALS undergoing surgical procedures. Combining LMA for ventilation further reduces the use of anesthetic drugs. This approach minimizes the risk of respiratory complications and provides a safe anesthetic experience. Anesthetic management in ALS patients requires careful planning and individualized strategies to optimize outcomes. Acknowledgments Not applicable. Authors’ contributions YXS: drafting the article. QWZ: Revising it critically for important intellectual content. XLC: Provide data collection. DW: Postoperative patient visits. YSP: final approval of the version to be published. All authors agreed to publish the article. Funding There is no financial support for this manuscript. Data availability Data generated and analyzed during this study are available from the corresponding author upon reasonable request. Email: pys609@163.com. Declarations We have confirmed that all participants / patients gave written informed consent to their personal or clinical details and the images to be published in this study. Ethics approval and consent to participate Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Data Availability Statement Data generated and analyzed during this study are available from the corresponding author upon reasonable request. Email: pys609@163.com.